Penzital Gastro, 80 pcs.

Pensital compensates insufficiency of external pancreatic secretory function, has proteolytic, amylolytic and lipolytic action.

Pancreatin enzymes (lipase, alpha-amylase, trypsin, chymotrypsin) contribute to the breakdown of proteins into amino acids, fat into glycerol and fatty acids, starch into dextrins and monosaccharides. It improves the functional state of the gastrointestinal tract and normalizes digestion.

Trypsin inhibits stimulated pancreatic secretion with analgesic effect.

Pancreatic enzymes are released from the dosage form in the alkaline environment of the small intestine because they are protected from the action of gastric juice by the coating.

The maximum enzymatic activity is observed 30-45 min after oral administration.

Indications

Replacement therapy for exocrine pancreatic insufficiency: chronic pancreatitis, pancreatectomy, condition after irradiation, dyspepsia, Roemheld syndrome (gastrocardiac syndrome), cystic fibrosis; flatulence, diarrhea of ​​non-infectious origin.

Impaired digestion of food (condition after resection of the stomach and small intestine); to improve food digestion in people with normal gastrointestinal function in case of errors in nutrition (eating fatty foods, large amounts of food, irregular meals) and in cases of chewing dysfunction, sedentary lifestyle, prolonged immobilization.

Preparation for X-ray examination and ultrasound of the abdominal organs.

Pharmacological effect

Penzital compensates for the insufficiency of the exocrine function of the pancreas and has proteolytic, amylolytic and lipolytic effects.

The enzymes included in pancreatin (lipase, alpha-amylase, trypsin, chymotrypsin) help break down proteins into amino acids, fats into glycerol and fatty acids, starch into dextrins and monosaccharides. Improves the functional state of the gastrointestinal tract, normalizes digestion processes.

Trypsin inhibits stimulated pancreatic secretion, producing an analgesic effect.

Pancreatic enzymes are released from the dosage form in the alkaline environment of the small intestine, because protected from the action of gastric juice by the membrane.

Maximum enzymatic activity is observed 30–45 minutes after oral administration.

Special instructions

The safety of using pancreatin during pregnancy has not been sufficiently studied. Use is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus. In case of cystic fibrosis, the use of pancreatin in high doses is not recommended due to the increased risk of developing strictures (fibrous colonopathy). The dose should be adequate to the amount of enzymes that is necessary for the absorption of fats, taking into account the quality and quantity of food consumed. With long-term use, iron supplements are prescribed simultaneously.

Active ingredient

Pancreatin

Composition

Each tablet contains:

Pancreatin 212.5 mg with enzyme activity:
lipase 6000 units FIP
amylase 4500 units FIP
protease 300 units FIP
Excipients: lactose, microcrystalline cellulose, sodium starch glycolate, povidone, talc, colloidal silicon dioxide, methacrylic acid copolymer, diethyl phthalate, titanium dioxide.

Contraindications

Hypersensitivity to the components of the drug, acute pancreatitis, exacerbation of chronic pancreatitis.

Side Effects

Allergic reactions.

In some cases – diarrhea, constipation, discomfort in the stomach, nausea (the cause-and-effect relationship of the development of these reactions with the action of pancreatin has not been established, since these phenomena refer to symptoms of exocrine pancreatic insufficiency).

With long-term use in high doses, the development of hyperuricosuria and an increase in the level of uric acid in the blood plasma is possible. In cystic fibrosis, if the required dose of pancreatin is exceeded, strictures (fibrous colonopathy) may develop in the ileocecal region of the ascending colon.

When using pancreatin in high doses in children, perianal irritation and irritation of the oral mucosa may occur.

Interaction

With the simultaneous use of pancreatin with iron preparations, the absorption of the latter may be reduced. The simultaneous use of antacids containing calcium carbonate and/or magnesium hydroxide may lead to a decrease in the effectiveness of pancreatin.

Overdose

Symptoms of hyperuricosuria, hyperuricemia. Children have constipation.

Treatment: drug withdrawal, symptomatic therapy.

Storage conditions

At a temperature not exceeding 25 °C, in a dry place out of reach of children.

Shelf life

3 years

Manufacturer

Shreya Life Sciences Pvt. Ltd, India